Equities
Health CarePharmaceuticals & Biotechnology
  • Price (USD)88.17
  • Today's Change0.56 / 0.64%
  • Shares traded5.10m
  • 1 Year change-8.60%
  • Beta1.6685
Data delayed at least 15 minutes, as of Dec 11 2018 21:00 GMT.
More ▼

Key statistics

On Tuesday, AbbVie Inc (ABBV:NYQ) closed at 88.17, 13.77% above the 52 week low of 77.50 set on Nov 01, 2018.
52-week range
Today
77.50Nov 01 2018125.86Jan 26 2018
Markit short selling activity
Low
Med
High
Open88.62
High89.44
Low86.66
Bid87.17
Offer90.31
Previous close88.17
Average volume6.36m
Shares outstanding1.50bn
Free float1.49bn
P/E (TTM)17.36
Market cap132.63bn USD
EPS (TTM)5.08
USD
Annual div (ADY)4.28
USD
Annual div yield (ADY)4.89%
Div ex-dateOct 12 2018
Div pay-dateNov 15 2018
Next div ex-dateJan 14 2019
Next div pay-dateFeb 15 2019
Data delayed at least 15 minutes, as of Dec 11 2018 21:00 GMT.
More ▼

Investors Chronicle View

The last IC recommendation on AbbVie Inc shares was Hold at 4,801.00 on 16 Jul 2014Read the full article
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.